Talk One : Better processes with “better” cells – engineering cells for enhanced manufacturability.
While much of the focus of gene engineering in the CGT field is on therapeutic activities, synthetic biology presents a significant opportunity to augment our approaches to cell manufacturing. How might we employ cell engineering strategies to improve product quality, reduce COGs, or better understand and control our manufacturing processes?
Confirmed speaker: Nick Timmins, VP Process Sciences, BlueRock Therapeutics, Canada
Talk Two: Title TBC
Confirmed speaker: Boaz Leshem, Vice President, Operations and Manufacturing, Pluristem, Israel